Gemin X Announces Positive Results in Small Cell Lung Cancer from Phase 1b Trial of Obatoclax at Annual Meeting of the American Society of Clinical Oncology
May 30th, 2009
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today presented positive results from a Phase 1b clinical trial of its lead product candidate obatoclax (GX15-070) for the treatment of first line patients with extensive-stage small cell lung cancer (SCLC).